perpetuity. It is made available under a CC-BY 4.0 International license .

1 Cytokine release syndrome-like serum responses after COVID-19 vaccination are frequent but 2 clinically inapparent in cancer patients under immune checkpoint therapy

3

4 Thomas Walle^{1,4,5,6*,#}, Sunanjay Bajaj^{1,5,6,#}, Joscha A. Kraske^{5,6}, Thomas Rösner^{5,6}, Christiane S. Cussigh⁷, Katharina A. Kälber⁷, Lisa Jasmin Müller⁸, Sophia Boyoung Strobel⁷, Jana Burghaus⁷, 5 Stefan Kallenberger^{5,6}, Christoph Stein-Thöringer^{2,5,6}, Maximilian Jenzer^{5,6}, Antonia Schubert^{,4,5,6,13,14}, 6 Steffen Kahle^{5,6}, Anja Williams^{5,6}, Birgit Hoyler¹, Lin Zielske¹⁰, Renate Skatula¹⁰, Stefanie Sawall¹, 7 Mathias F. Leber^{1,5,6}, Russell Z. Kunes¹¹, Johannes Krisam¹², Carlo Fremd^{5,6,9}, Andreas 8 Schneeweiss⁹, Jürgen Krauss^{5,6}, Anne Katrin Berger^{5,6}, Georg M. Haag^{5,6}, Stefanie Zschäbitz^{5,6}, Niels 9 Halama^{3,5,6}, Christoph Springfeld^{5,6}, Romy Kirsten¹⁰, Jessica C. Hassel⁷, Dirk Jäger⁵, NCT 10 ANTICIPATE Investigators & Guy Ungerechts^{1,4,5,6,13} 11

12 NCT ANTICIPATE Investigators: Thomas Walle^{1,4,5,6*,#}, Joscha A. Kraske^{5,6}, Thomas Rösner^{5,6}, 13 Christiane Cussigh⁷, Katharina Kälber⁷, Lisa Jasmin Müller⁸, Sophia Boyoung Strobel⁷, Jana Burghaus⁷, Stefan Kallenberger^{5,6}, Christoph Stein-Thöringer^{2,5,6}, Maximilian Jenzer^{5,6}, Antonia 14 15 Schubert^{4,5,6,13,14}, Steffen Kahle^{5,6}, Anja Williams^{5,6}, Omar Abdelrahim^{5,6}, Elena Busch^{5,6}, Patrick 16 Derigs⁸, Katharina Dischinger^{5,6}, Fouad Mitri⁷, Kerstin Schmidt^{5,6}, Irfan A. Bhatti^{5,6}, Barbara Grün^{5,6}, Nicolas Hohmann^{5,6}, Lena Woydack^{5,6}, Xin-Wen Zhang^{5,6}, Dyke Ferber^{5,6}, Andreas Mock^{5,6}, Tillmann 17 Pompecki¹⁵, Timo Schank⁷, Carlo Fremd⁹, Andreas Schneeweiss⁹, Jürgen Krauss^{5,6}, Anne Berger^{5,6}, 18 Georg M. Haag^{5,6}, Stefanie Zschäbitz^{5,6}, Niels Halama^{3,5,6}, Christoph Springfeld^{5,6}, Romy Kirsten¹⁰, 19

Jessica C. Hassel⁷, Dirk Jäger^{5,6} & Guy Ungerechts^{1,4,5,6,16} 20

- 22 ¹Clinical Cooperation Unit Virotherapy, German Cancer Research Center (DKFZ), Heidelberg,
- 23 Germany
- 24 ²Division Microbiome and Cancer, German Cancer Research Center (DKFZ), Heidelberg, Germany.
- 25 ³Department of Translational Immunotherapy, German Cancer Research Center (DKFZ), Heidelberg, 26 Germany.
- 27 ⁴German Cancer Consortium (DKTK), Heidelberg, Germany
- 28 ⁵Department of Medical Oncology, National Center for Tumor Diseases (NCT), Heidelberg, Germany
- 29 ⁶Department of Medical Oncology, University Hospital Heidelberg, Heidelberg, Germany
- 30 ⁷Department of Dermatology and National Center for Tumor Diseases, University Hospital Heidelberg, 31 Heidelberg, Germany
- 32 ⁸Department of Hematology, University Hospital Heidelberg, Heidelberg, Germany
- 33 ⁹Department of Gynecological Oncology, National Center for Tumor Diseases (NCT), Heidelberg, 34 Germany
- 35 ¹⁰NCT Liquid Biobank, National Center for Tumor Diseases (NCT), Heidelberg, Germany
- 36 ¹¹Department of Statistics, Columbia University, New York, NY 10027, USA
- 37 ¹²Institute of Medical Biometry, Heidelberg University, Heidelberg, Germany
- 38 ¹³BioQuant & Department of Cell and Molecular Biology, Heidelberg University, Heidelberg, Germany
- 39 ¹⁴Division Signaling and Functional Genomics German Cancer Research Center (DKFZ), Heidelberg, 40 Germany
- 41 ¹⁵Department of Gastroenterology, University Hospital Heidelberg, Heidelberg, Germany
- 42 ¹⁶Ottawa Hospital Research Institute, Cancer Therapeutics Program, 501 Smyth Road, Ottawa,
- Ontario, Canada 43
- 44 *Corresponding author/lead contact: T.W. t.walle@dkfz.de
- 45 #Equal contribution
- 46 NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

47 Abstract

Cancer patients frequently receive immune checkpoint therapies (ICT) which may modulate 48 immune responses to COVID-19 vaccines. Recently, cytokine release syndrome (CRS) was 49 observed in a cancer patient who received the BTN162b2 vaccine under ICT. Here, we 50 51 analyzed adverse events (AEs) in patients of various solid tumor types undergoing (n=64) or not undergoing (n=26) COVID-19 vaccination under ICT as an exploratory endpoint of a 52 53 prospectively planned cohort study. We did not observe clinically relevant CRS after vaccination (95% CI [0,0.056]). Short term (<4 weeks) serious AEs were rare (12.5%) and 54 55 overall AEs under ICT were comparable to unvaccinated patients. Despite the absence of 56 CRS symptoms, we observed a pairwise-correlated set of CRS-associated cytokines upregulated in 42% of patients after vaccination and ICT (>1.5fold). Hence, clinically 57 58 meaningful CRS appears to be rare in cancer patients under ICT and elevated serum cytokine 59 levels are common but not sufficient to establish CRS diagnosis.

61 Introduction

62 Patients with solid tumors have an increased fatality risk after infection with the SARS-CoV-2 coronavirus (Russell et al., 2021). Cancer patients have therefore been prioritized for 63 vaccination against SARS-CoV-2 (COVID-19 vaccination) in many countries (Ribas et al., 64 2021; Trapani & Curigliano, 2021). Approved vaccines in Europe and the United States use 65 mRNA lipid nanoparticles or viral vectors to transiently transfect/transduce a SARS-CoV-2 66 spike mRNA/transgene which is translated in the patient's healthy cells at the site of 67 vaccination, thus strongly inducing cellular and humoral adaptive immunity (Baden et al., 2020; 68 69 Fendler et al., 2021; Folegatti et al., 2020; Frenck et al., 2021; Sahin et al., 2014). However, 70 cancer patients were underrepresented in clinical phase III trials leading to FDA and EMA approval of these vaccines (Baden et al., 2020; Folegatti et al., 2020; Polack et al., 2020). 71 Moreover, an increasing number of cancer patients receive immunomodulatory cancer 72 73 therapies, mostly immune checkpoint therapies (ICT) blocking the PD-1/PD-L1 coinhibitory 74 axis for T cell activation (Haslam & Prasad, 2019). Since ICT leads to reactivation of tumor antigen-reactive T cells, it is possible that ICT may also influence activation of SARS-CoV-2 75 76 spike protein (S1)-specific T cells. This increased T cell activation may lead to massive 77 cytokine release and subsequent clinical reactions. The body's systemic reaction to the 78 resulting release of multiple inflammatory cytokines from T and myeloid cells is called cytokine 79 release syndrome (CRS). CRS manifests itself in fever, hypotension, hypoxia and multiorgan 80 dysfunction at later stages (Lee et al., 2019). Most frequently such responses are observed after adoptive T cell therapies, bispecific antibodies to the CD3 co-receptor or severe infection 81 (Fajgenbaum & June, 2020). CRS is commonly graded according to the Common Terminology 82 of Adverse Events (CTCAE) or the American Society for Transplantation and Cellular Therapy 83 (ASTCT) consensus grading (Fajgenbaum & June, 2020; Lee et al., 2019). However, fever 84 85 ≥38°C alone is sufficient to establish CTCAE grade 1 CRS, which does not account for mild fever as part of many appropriate immune reactions. Hence, an exhaustive differential 86 diagnosis is essential in establishing CRS (Fajgenbaum & June, 2020). 87

Au et al. recently reported a patient with CRS without evidence for infection after COVID-19 vaccination under ICT. This patient required hospitalization due to fever, thrombocytopenia (grade 3 CTCAE 4.03, grade 1 ASTCT) as well as increased c-reactive protein levels (CRP > 200mg/l), prompting questions about the frequency of CRS in cancer patients under ICT. However, it remains unclear how frequently CRS occurs, and whether cytokine profiles could be explored to identify ICT-treated cancer patients at risk for CRS at early stages.

Here, we assessed adverse events, clinical laboratory data and serum cytokine responses in
patients undergoing combined ICT and COVID-19 vaccination as an exploratory endpoint of
a prospectively registered single center cohort study.

97 Results


98 A pan-tumor cohort study across diverse immune combination therapies

Between 2nd December 2019 and 20th July 2021, we screened 301 patients, of which 190 were 99 100 screened prospectively and 111 retrospectively as defined in the trial protocol (German Clinical Trials Register, DRKS00022890). Of these patients, 29 patients with dermatological 101 102 cancers were also included in a retrospective survey study at our center (Strobel et al, manuscript in revision). We recruited 220 patients with advanced solid tumors undergoing 103 immune checkpoint therapy (ICT) at our center (Figure 1A). These patients received regular 104 blood sampling before and during therapy and were monitored for adverse events. We 105 106 assessed the COVID-19 vaccination status of the patients within the cohort during treatment follow-up and identified 64 patients who received a COVID-19 vaccine while under ICT and 107 108 26 patients who did not (Figure 1A, B). The remaining patients either died before the vaccine 109 was widely available (n=52), did not have their vaccination status assessed (n=52), were lost 110 to follow up (n=15), refused to disclose their vaccination status (n=5) or received COVID-19 vaccinations before ICT (n=6) (Figure 1A). 111

We focused further analyses on the 90 patients with known vaccination status (Table 1). 23 cancer types were represented within this patient group, the most frequent being skin

melanoma (n=21), hepatocellular carcinoma (n=11) and renal cell carcinoma (n=9) (Table 1, 114 Figure 1C). Therapies included a variety of combinatorial immunomodulatory therapies, most 115 frequently anti-PD-1/PD-L1 monotherapy (n=35), combined anti-PD-1 and anti-CTLA-4 116 therapy (n=15), and a combination of anti-PD-1/PD-L1 with anti-VEGF (n=11) (Table 1, Figure 117 118 1D). Despite the limited patient sizes of our cohorts, vaccinated and unvaccinated patients showed similar clinical characteristics such as sex, age, tumor type, stage, comorbidities, 119 therapy regimen and line of therapy (Table 1) and were hence deemed suitable for further 120 121 comparisons.







124 Figure 1 - A pan-tumor cohort study across diverse immune combination therapies

(A) CONSORT flow chart indicating patient screening data and cohorts for subsequent dataanalysis.

- (B) Stacked bar-graph depicting the type of COVID-19 vaccination for vaccinated patients(n=64).
- (C) Stacked bar-graph indicating tumor types of vaccinated (n=64) and unvaccinated (n=26)
 patients.
- 131 (D) Stacked bar-graph indicating immune combination therapies of vaccinated (n=64) and
- 132 unvaccinated (n=26) patients.

Table 1 - Characteristics of analyzed patients at baseline 133

Characteristic	Vaccinated	Unvaccinated	Total
	(n=64)	(n=26)	(n=90)
Patient recruitment characteristics		l` í	
Vaccination period (MM/YY-MM/YY)	01/21-07/21	-	01/21-07/21
Follow-up from 1 st vaccine – days	24-259 (169)	-	24-259 (169)
(median)			
Start of ICT period (MM/YY-MM/YY)	03/20-05/21	07/20-07/21	03/20-07/21
Follow-up from ICT – days (median)	44-574 (254)	30-441 (203.5)	30-574 (229)
Vaccination type – n (%) BNT162b2	49 (75 0)		49 (52 2)
mRNA-1273	48 (75.0) 3 (4.7)	-	48 (53.3) 3 (3.3)
AZD1222	9 (14.1)	-	9 (10.0)
AZD1222/mRNA-1273	1 (1.6)	-	1 (1.1)
Not specified	3 (4.7)	-	3 (3.3)
Sex – n (%)			
Male	44 (68.8)	19 (73.1)	63 (70.0)
Female	20 (31.3)	7 (26.9)	27 (30.0)
Age group at treatment – n (%)			
18-60	19 (29.7)	7 (26.9)	26 (28.9)
>60	45 (70.3)	19 (73.1)	64 (71.1)
ECOG – n (%)		7 (00 0)	
0	11 (17.2)	7 (26.9)	18 (20.0)
1	46 (71.9)	13 (50.0)	59 (65.6)
2 3	7 (10.9)	4 (15.4)	11 (12.2)
4-5	0 (0.0) 0 (0.0)	2 (7.7) 0 (0.0)	2 (2.2) 0 (0.0)
Cancer type – n (%) [#]	0 (0.0)	0 (0.0)	0 (0.0)
SKCM	15 (23.4)	6 (23.1)	21 (23.3)
LIHC	9 (14.1)	2 (7.7)	11 (12.2)
KIRC	6 (9.4)	3 (11.5)	9 (10.0)
UCA	6 (9.4)	2 (7.7)	8 (8.9)
UVM	4 (6.3)	2 (7.7)	6 (6.7)
NEC	3 (4.7)	1 (3.8)	4 (4.4)
HNSC	2 (3.1)	2 (7.7)	4 (4.4)
AEG	3 (4.7)	2 (7.7)	5 (5.6)
PAAD	2 (3.1)	-	2 (2.2)
MER	2 (3.1)	-	2 (2.2)
BRCA	2 (3.1)	1 (3.8)	3 (3.3)
Other* UICC stage at diagnosis – n (%)	10 (15.6)	5 (19.2)	15 (16.7)
	8 (12.5)	4 (15.4)	12 (13.3)
	10 (15.6)	6 (23.1)	16 (17.8)
	11 (17.2)	8 (30.8)	19 (21.1)
IV	34 (53.1)	7 (26.9)	41 (45.6)
unknown (not IV)	1 (1.6)	1 (3.8)	2 (2.2)
Line of therapy – n (%)	, <i>i</i>		. ,
1L	38 (59.3)	15 (57.7)	53 (58.9)
2L	13 (20.3)	4 (15.4)	17 (18.9)
3-5L	10 (15.6)	6 (23.1)	16 (17.8)
≥6L	3 (4.7)	1 (3.8)	4 (4.4)
Other comorbidities – n (%) [¥]	20(4E2)	0 (24 6)	20 (42 2)
Arterial Hypertension Coronary heart disease	29 (45.3)	9 (34.6) 2 (7.7)	38 (42.2) 10 (11.1)
Other Cardiomyopathy	8 (12.5) 2 (3.1)	2 (7.7) 3 (11.5)	5 (5.6)
Cerebrovascular disease/ Peripheral	6 (9.4)	2 (7.7)	8 (8.9)
vascular disease		- (' '')	0 (0.0)
Chronic pulmonary disease	2 (3.1)	1 (3.8)	3 (3.3)
Diabetes	8 (12.5)	6 (23.1)	14 (15.6)
Other endocrine disorder	12 (18.8)	5 (19.2)	17 (18.9)
Hepatic disease	6 (9.4)	3 (11.5)	9 (10.0)
Renal disease	5 (7.8)	5 (19.2)	10 (11.1)
Rheumatic disease	2 (3.1)	3 (11.5)	5 (5.6)
No Comorbidities	4 (6.3)	0 (0)	4 (4.4)

perpetuity. It is made available under a CC-BY 4.0 International license .

BMI – n (%)			
<18.5	1 (1.6)	2 (7.7)	3 (3.3)
≥18.5 - <25.0	29 (45.3)	8 (30.8)	37 (41.1)
≥25.0 - <30.0	13 (20.3)	7 (26.9)	20 (22.2)
≥30.0	8 (12.5)	4 (15.4)	12 (13.3)
NA	13 (20.3)	5 (19.2)	18 (20.0)
Treatment – n (%) ^f			
PD-1/PD-L1 mono	24 (37.5)	11 (42.3)	35 (38.9)
CTLA-4 + PD-1/PD-L1	9 (14.1)	6 (23.1)	15 (16.7)
CTLA-4 mono	1 (1.6)	1 (3.8)	2 (2.2)
PD-1/PD-L1 + CTX	5 (7.8)	3 (11.5)	8 (8.9)
PD-1/PD-L1 + TKI	6 (9.4)	3 (11.5)	9 (10.0)
PD-1/PD-L1 + VEGF	9 (14.1)	2 (7.7)	11 (12.2)
PD-1/PD-L1 + RTX	2 (3.1)	-	2 (2.2)
PD-1/PD-L1 other	8 (12.5)	-	8 (8.9)

* Others include Ampullary carcinoma, Adrenocortical carcinoma, Cholangiocarcinoma, Carcinoma of unknown primary, Dermal squamous cell carcinoma, Esophageal squamous cell carcinoma, Head and neck mucosal melanoma, Kidney renal papillary cell carcinoma, Lung adenocarcinoma, Neuroendocrine tumor, Oral squamous cell carcinoma and RCC – Renal cell carcinoma.

AEG - Adenocarcinoma of the esophagogastric junction, BRCA – Breast cancer, HNSC – Head and neck squamous cell carcinoma, KIRC – Clear cell renal cell carcinoma, LIHC – Liver hepatocellular carcinoma, MER – Merkel cell carcinoma, NEC – Neuroendocrine carcinoma, PAAD – Pancreatic adenocarcinoma, SKCM – Skin cutaneous melanoma, UCA – Urothelial carcinoma, UVM – Uveal melanoma.
 * Number of patients with comorbidity listed. Patients can have multiple comorbidities.
 ^f CTX – Chemotherapy, NA: not available, RTX – Radiotherapy, TKI – Tyrosine Kinase Inhibitor, VEGF – Vascular Endothelial Growth Factor Antibody. ICT – Immune Checkpoint Therapy - - Not applicable

135

Cytokine release syndrome is infrequent after COVID-19 vaccination under immune checkpoint therapy

138 To estimate safety of COVID-19 vaccination under ICT, we analyzed early adverse events (AE) from the first until 4 weeks after the second COVID-19 vaccination dose (Table 2, Figure 139 2A). While fewer early local adverse events such as pain at the injection site (n=2, 3.1%) were 140 141 reported in our cohort, early systemic AEs were comparable to reported AEs in cancer patients including patients under ICT (Monin et al., 2021; Waissengrin et al., 2021). The most common 142 systemic AEs included fatigue (n=10, 15.6%), muscle weakness (n=8, 12.5%) and fever (n=4, 143 6.3%) (Figure 2B, Table 2). Seven patients (10.9%) were hospitalized due to grade \geq 3 AEs 144 and three of these patients died (4.7%) (Figure 2B). One patient who received the BNT162b2 145 vaccine was admitted after grade 4 anemia due to esophageal varices bleeding and recovered 146 quickly under high-dose proton pump inhibitor therapy. A second patient experienced grade 3 147 148 increase of transaminases under pembrolizumab + axitinib and the mRNA-1273 vaccine which normalized within three weeks after initial IV methylprednisolone and subsequent oral 149 150 glucocorticoid tapering. Another patient already exhibited grade 2 diarrhea before BNT162b2

151 vaccination which worsened to grade 3 two weeks after vaccination. Multiplex-PCR analyses of stool showed Clostridium difficile, and symptoms improved after therapy with IV fluids and 152 antibiotics. Another patient who received the AZD1222 vaccine was admitted due to grade 3 153 diarrhea for which no infectious cause could be determined and was therefore deemed ICT-154 155 related. Symptoms resolved under IV fluids and corticosteroids with oral tapering. Two patients were admitted after CT confirmed fulminant hepatic disease progression causing cholestasis 156 and both patients ultimately died. Finally, one patient with a history of combined severe aortic 157 stenosis (0,8cm² aortic valve area) and aortic insufficiency died at home after cardiac 158 159 decompensation with pleural effusion and lower limb edema after AZD1222 administration.

Adverse Event	Any grade	Grade ≥3
Any adverse event – n (%)	40 (62.5)	8 (12.5)
No adverse events – n (%)	24 (37.5)	62 (87.5)
Adverse event – n (%)		
Fatigue	10 (15.6)	2 (3.1)
Pain at injection site	2 (3.1)	0 (0.0)
Muscle weakness	8 (12.5)	3 (4.7)
Arthralgia	1 (1.6)	0 (0.0)
Fever	4 (6.3)	0 (0.0)
Infection	4 (6.3)	3 (4.7)
Nausea	2 (3.1)	0 (0.0)
Headache	2 (3.1)	0 (0.0)
Vomiting	1 (1.6)	0 (0.0)
Upper GI bleeding	1 (1.6)	1 (1.6)
CRS grade ≥2	0 (0.0)	0 (0.0)
Laboratory abnormalities - n (%)		
Anemia	7 (10.9)	1 (1.6)
Thrombocytopenia	8 (12.5)	1 (1.6)
Bilirubin increase	9 (14.1)	1 (1.6)
Creatinine increase	6 (9.4)	1 (1.6)
Death – n (%)	3 (4.7)	• • •

160 Table 2 - Early adverse events after COVID-19 vaccination (<4 weeks)




Figure 2 – Early adverse events after COVID-19 vaccination under immune checkpoint therapy 163

164 (A) Schematic timeline depicting the start and duration of follow-up and vaccination timepoints of

vaccinated and unvaccinated patients 165

166 (B) Tree maps visualizing the proportion and the numbers of all and grade \geq 3 AEs up to 4 weeks after 167 vaccination in vaccinated patients (n=64).

168 (C) Line-plots indicating platelet counts (n=61, left panel) and c-reactive protein concentrations ((CRP,

169 n=55, right panel) either after the first vaccine dose (upper panels) or second vaccine dose (lower

170 panels). Reference ranges are indicated in green shading. Lines are colored according to the

171 vaccination schema used with the color code indicated below. NA: not available.

172


We observed no clinically relevant CRS in our patient cohort, defined as all CRS without 173 evidence for infection identified by either the CTCAE v5.0 or ASTCT 2019 criteria (95% CI 174 [0,0.056]). We excluded patients with fever alone without constitutional symptoms, which may 175 reflect appropriate inflammatory reactions (Fajgenbaum & June, 2020). In the above-176 mentioned case report (Au et al., 2021) CRS was associated with thrombocytopenia and c-177 178 reactive protein (CRP) increase. In our cohort, only one patient experienced grade ≥3 thrombocytopenia with a platelet count of 5/nl four days after the 2nd BNT162b2 dose. This 179 patient had received gemcitabine and carboplatin three days prior to the event while still under 180 prednisolone (50mg/d) due to a grade 3 autoimmune hemolytic anemia, which started after a 181 182 blood transfusion two months earlier. The patient was asymptomatic, afebrile and was not 183 hospitalized. Moreover, platelet counts spontaneously normalized within 2 weeks thus making CRS unlikely. We frequently observed mild (>30mg/l and >1.5-fold) CRP increase after 184 vaccination (n= 22, 40% after 1st dose; n=17, 35% after 2nd dose) (Figure 2C). One patient 185 showed a severe CRP increase (80 to 289mg/l) peaking 7 days after the 2nd BNT162b2 dose 186 187 (Figure 2C). This patient was also asymptomatic including absence of fever/hypotension or hypoxia, thus making CRS unlikely. Blood and urine cultures remained negative, and CRP 188 spontaneously dropped below 100mg/l within 2 weeks. Hence, we did not observe any 189 clinically apparent CRS after COVID-19 vaccination in our cohort suggesting that CRS may 190 be rare in patients under ICT and concurrent COVID-19 vaccination. 191


193 Asymptomatic CRS-like serum response patterns after COVID-19 vaccination under ICT

To evaluate cytokine responses indicative of CRS, we analyzed serum levels of CRSassociated cytokines in 37 patients undergoing concurrent ICT and COVID-19 vaccination with a baseline sample \leq 6 months before vaccination and a sample \leq 6 weeks after vaccination (Figure 3A-B). We excluded one patient who had an immune related adverse event (arthritis grade 3) at baseline before vaccination.

To analyze cytokines induced by vaccination under ICT, we performed pairwise correlation of 199 200 all measured cytokines, which yielded four clusters of pairwise correlated cytokine programs (colored sidebars, Figure 3A). To assess the stability of this clustering we bootstrapped the 201 202 probability of each pair of cytokines falling into the same cluster (see Methods). Bootstrapping 203 confirmed the stability of cytokine programs 2 and 3 while the other clusters were more heterogeneous (Figure 3B). Assessment of the log fold change of cytokine concentrations 204 205 indicated that cytokine programs 2 and 3 were upregulated after vaccination in most patients 206 although only program 2 was statistically significant when correcting for multiple comparisons (p=0.006, q=0.03) (Figure 3C). Program 3 (p=0.04, q=0.09) included mediators previously 207 described in CRS after the BNT162b2 vaccine in an anti-PD-1 treated cancer patient such as 208 IL-18 and sIL-2RA (Au et al., 2021). Program 2 included hallmark CRS-cytokines and CRS-209 210 mediators indicative of T cell (IL-2) and myeloid cell activation (IL-6, CXCL8 = IL-8, CCL2, sIL-211 1R) (Figure 3D). IL-6 has been linked to CRS severity in multiple studies and surpassed 50pg/ml (research grade measurement) in 8 patients (22.2%), levels frequently observed in 212 213 patients with severe COVID-19 or CAR-T cell induced CRS (Chen et al., 2021; Galván-Román 214 et al., 2021; Hay et al., 2017) (Figure 3D). Stratification by patient characteristics revealed that cytokine program 2 was predominantly upregulated after BNT162b2 vaccination although only 215 216 few patients received other vaccines in our study (Figure S1). Moreover, induction of cytokine program 2 was more frequent in male patients across a broad array of tumor types (Figure 217 218 S1). Overall, our results suggest induction of CRS-related cytokines as a frequent but clinically 219 inapparent event after COVID-19 vaccination in ICT treated cancer patients.








perpetuity. It is made available under a CC-BY 4.0 International license .

- (A) Heatmap indicating spearman correlation indices of log(fold change) cytokine concentrations after
- 224 COVID-19 vaccination from n=38 patients. Color bars on the sides indicate clusters obtained from
- 225 hierarchical clustering.
- (B) Heatmap indicating probability of each pair of cytokines clustering together as calculated by
 bootstrapping (n=10000) from n=38 patients.
- 228 (C) Heatmaps indicating 10log-fold change of cytokine concentrations after vaccination. Bar graph on
- the side indicates average 10log-fold change of cytokines in each row with concentrations after the first
- 230 or second vaccination dose labeled according to the color code below from n=38 patients. P-values
- 231 (two-tailed) were calculated using a Wilcoxon signed rank test.
- 232 (D) Line-plots indicating cytokine concentrations of cytokine program 2 cytokines after vaccination
- from n=38 patients.
- 234





236 Figure S1 - Cytokine program 2 upregulation stratified by patient characteristics

Box-plots indicating average 10log(fold change) of cytokine program 2 after COVID-19 vaccination
 stratified according to vaccine type (left panel), sex (middle panel) or tumor type (right panel, n=38).
 P-value was calculated using a Mann-Whitney U-test.

240

241 Comparable adverse events in COVID-19 vaccinated and unvaccinated patients under


242 **ICT**

To assess whether vaccination increased the frequency of ICT-related adverse events at later 243 244 timepoints we compared AE frequencies in vaccinated (n=64) and unvaccinated patients (n=26) over the entire course of ICT. We did not detect any significant differences in all grade 245 246 or grade \geq 3 AEs between vaccinated and unvaccinated patients under ICT (Figure 4A-B). One patient experienced CRS grade 2 before COVID-19 vaccination but no patient showed CRS 247 248 after vaccination. Immune related AE were numerically more frequent in unvaccinated patients 249 while vaccinated patients had a higher frequency of fatigue, nausea and lower grade infections although these differences were not statistically significant (Figure 4A-B, Table 3). To confirm 250 251 the accuracy of this comparison, we calculated propensity scores based on age and sex and


matched vaccinated and unvaccinated patients according to this score (Figure S2A-B). For this purpose, we assigned unvaccinated patients a "virtual" vaccination date at the same time interval from the start of ICT as their vaccinated matched counterparts (Figure S2A). Again, overall and grade ≥3 adverse events were comparable between the matched cohorts (Figure S2C) suggesting that it is unlikely that COVID-19 vaccination profoundly increases the incidence of severe adverse events in ICT-treated cancer patients.

258 Starting from 15th October 2020, all patients were screened for COVID-19 at every therapy session generally every 1-4 weeks using a rapid antigen test fulfilling the guality criteria of the 259 260 German Federal Institute for Vaccines and Biomedicines. We detected two COVID-19 cases in the unvaccinated cohort (7.7%, 95% CI [1.6%, 22.5%]) which had to be hospitalized for 261 severe pneumonia. One patient recovered and was able to resume therapy 6 weeks later but 262 263 died two months after due to disease progression. The other patient died from COVID-19 264 pneumonia on the intensive care unit. We detected no COVID-19 cases in the vaccinated 265 patient cohort, despite regular screening (95% CI [0,5.6%]). Accordingly, patient serum post 266 vaccination neutralized SARS-CoV-2 S1 protein binding to recombinant human ACE2 in a competitive immunoassav (Figure S3). Hence, our results corroborate the increasing evidence 267 268 that the here investigated COVID-19 vaccines have clinically meaningful efficacy in ICT 269 treated cancer patients (Fendler et al., 2021; Monin et al., 2021).

To explore whether vaccination status was associated with oncological outcomes, we 270 compared overall survival of vaccinated and unvaccinated patients (Figure 4C). Vaccinated 271 272 patients showed prolonged survival as compared to unvaccinated patients (HR 0.24, p=0.002) 273 (Figure 4C). This effect could not be explained by COVID-19 related deaths alone (Supplementary Table 1) but was stable in all relevant patient subgroups (Figure S4). 274 275 Moreover, we confirmed this result in a Cox proportional hazards model where vaccination 276 status was the strongest predictor of prolonged overall survival (coefficient -1.54, 95% CI [-277 2.69,-0.40], p=0.01) (Figure 4D). Hence, these data suggest an unexpected association of 278 COVID-19 vaccination and prolonged overall survival in our patient cohort.







(A-B) Grouped bar plots indicating the frequency of overall adverse event (A) or grade \geq 3 adverse 282 events (B) under immune checkpoint therapy in vaccinated (n=64) and unvaccinated (n=26) patients. 283 (C) Kaplan-Meier curve indicating overall survival probability of vaccinated (n=64) and unvaccinated 284 (n=26) patients under immune checkpoint therapy. P values and hazard ratios were calculated using 285 286 a log-rank test.

- 287 (D) Forest plot indicating the results of the Cox proportional hazards model of n=90 patients with
- 288 boxes indicating the 10log(hazard ratio) and whiskers indicating the 95% confidence interval. P values
- 289 (two-tailed) and number (no.) of events are indicated on the left.

290

Table 3 - Immune related adverse events under immunotherapy in vaccinated and non-291

292 vaccinated patients


- 293 Table indicating immune related adverse event frequencies with P values calculated using
- Fisher's exact test. 294

Characteristic – n (%)	Vaccinated (n=64)	Unvaccinated (n=26)	P value
Any AE	62 (96.9)	25 (96.2)	0.99
	· · · · ·		
Grade ≥3	31 (48,4)	18 (69.2)	0.10
AI-Pneumonitis	2 (3.1)	3 (11.5)	0.14
AI-Colitis	5 (7.8)	5 (19.2)	0.15
AI-Hepatitis	6 (9.4)	3 (11.5)	0.71
AI-Hypophysitis	3 (4.7)	1 (3.9)	0.99
AI-Pancreatitis	0 (0.0)	1 (3.9)	0.29
AI-Nephritis	2 (3.1)	1 (3.9)	0.99
AI-Thrombocytopenia	0 (0.0)	1 (3.9)	0.29
AI-Hemolytic Anemia	1 (1.6)	0 (0.0)	0.99
AI-Thyroiditis	3 (4.7)	0 (0.0)	0.55
AI-Miositis/Arthritis	3 (4.7)	1 (3.9)	0.99
AI-Radiculitis	1 (1.6)	0 (0.0)	0.99

295

Supplementary Table 1 - Cause of death in vaccinated and non-vaccinated patients Table indicating causes of death in vaccinated and unvaccinated patients. PD - progressive disease.

Patient vaccination status	Cause of death
Unvaccinated	COVID-19 Pneumonia
	Pulmonary metastases PD, respiratory insufficiency
	Pulmonary metastases PD, respiratory insufficiency
	Laryngeal PD, respiratory insufficiency
	Respiratory Insufficiency
	Intracerebral metastasis hemorrhage
	Liver metastases PD, liver failure
	Kidney failure
	Unknown, patient declined therapy continuation
Vaccinated	Cardiopulmonary decompensation
	Aortic stenosis, cardiopulmonary decompensation
	Hepatic metastases PD, liver failure
	Hepatic metastases PD, liver failure
	Cholangiosepsis





301

Figure S2 - Comparable adverse events in sex and age matched COVID-19 vaccinated 302 and unvaccinated immune checkpoint therapy treated cancer patients 303

- (A) Schema indicating the propensity score based matching procedure 304
- 305 (B) Box plots indicating the proportional difference of sex before and after propensity score
- matching (upper panel). Xy plot indicating the empirical cumulative distribution function of 306

307 vaccinated and unvaccinated cohorts before and after matching.







315 Figure S3 - S1 neutralizing antibody concentrations after COVID-19 vaccination in ICT-

treated patients 316

Line-plot indicating neutralizing antibody concentrations of individual patients after vaccination as 317

- assessed by an ACE2 S1 competitive immunoassay (research grade). Color code on the right 318
- 319 indicating vaccine used in the respective patients.

321




Figure S4 – Vaccination is associated with of overall survival probability across patient 323 324 subaroups

Forest-plot indicating hazard ratios (HR, boxes) and 95% confidence intervals (CI, whiskers) of 325

vaccinated and unvaccinated patients stratified into the subgroups indicated with the exact 326 number (no.) of events and patients at risk for each subgroup as well as the 95% CIs indicated 327

328 on the left. Hazard ratios and confidence intervals were calculated using a Log-rank test or

Mantel-Hanszel method if no events were observed in one group. Diagn.: diagnosis. 329

331 Discussion

In a prospectively planned cohort study, we here describe a set of CRS-related cytokines commonly upregulated after COVID-19 vaccination in ICT treated cancer patients despite the absence of clinical CRS phenotypes. None of our patients showed evidence for clinically relevant CRS after vaccination suggesting that CRS is an infrequent event after COVID-19 vaccination under ICT. Moreover, comparison to unvaccinated patients suggested that COVID-19 vaccination does not profoundly increase the rate of immune related or grade \geq 3 adverse events but may decrease the rate of COVID-19 infection in ICT treated patients.

A recent case report of CRS after vaccination in a colorectal cancer patient treated with anti-339 340 PD-1 ICT (Au et al., 2021) highlighted the insufficient evidence regarding vaccine-related adverse events in ICT treated cancer patients. Au and colleagues presented a patient with 341 fever, thrombocytopenia, CRP increase and elevation of several cytokines including IFN-y, 342 343 sIL-2R, IL-18, IL-16, IL-10 after vaccination and ICT as compared to cytokine levels before 344 initiation of ICT and vaccination (Au et al., 2021). In our study we did not observe any CRS (95%CI [0,5.6%]) after COVID-19 vaccination after both short-term (1st dose until 4 weeks 345 after 2nd dose) and long-term follow-up (med. follow-up = 24 weeks after 1st dose). Moreover, 346 AE under immunotherapy were comparable in vaccinated and unvaccinated patients. Thus, 347 348 CRS is likely an infrequent event under combined ICT and COVID-19 vaccination.

349 Despite the absence of clinically relevant CRS, we observed a set of CRS-related cytokines 350 coordinately and commonly induced after COVID-19 vaccination under ICT. This included the CRS hallmark cytokine IL-6 and other CRS-related cytokines (CXCL8, IL-2, CCL2, sIL1-RA). 351 Induction of IL-6 has been reported after mRNA-based lipoplex tumor vaccination and 352 353 symptoms are generally mild and self-limiting (Sahin, Oehm, et al., 2020). Moreover, we found higher IL-2 levels after vaccination, which may be explained by T cell activation and preferable 354 TH1 T cell polarization as shown in healthy adults vaccinated with BNT162b2 (Sahin, Muik, et 355 al., 2020). Our patients also showed coordinated release of CCL2 and CXCL8 levels after 356 357 COVID-19 vaccination which can be explained by the activation of myeloid cells by the mRNA

358 loaded lipid nanoparticles of the BNT162b2 vaccine (Liang et al., 2017). While CCL2 and IL-359 2 were also reported to be induced in the above-mentioned case report of CRS in a mismatch 360 repair deficient colorectal cancer (CRC) patient, the CRS hallmark cytokines IL-6 and CXCL8 361 levels remained largely constant in this patient (Au et al., 2021). Our study did not include a 362 CRC or mismatch-repair deficient patient who received COVID-19 vaccination. It is possible 363 that the clinical course observed by Au et al. is a CRC or mismatch repair deficiency specific 364 effect given the distinct T cell inhibitory mechanisms in these tumors which may render T cells 365 more responsive to PD-1 disinhibition (Au et al., 2021; Pelka et al.). 366 Notably, one patient in our study experienced grade 2 CRS before any COVID-19 vaccination was administered, highlighting that CRS can occur independent of vaccination under ICT and 367 may not necessarily be vaccine-related. This is particularly important in cancer patients in a 368 palliative setting with limited treatment options, as CRS treatments such as glucocorticoids 369 370 may impair ICT efficacy and deprive patients of an important treatment option (lorgulescu et al., 2021; Maslov et al., 2021). Our results suggest that CRS-related cytokines are commonly 371 induced after COVID-19 vaccination and not sufficient to establish the diagnosis of CRS. 372 Clinically relevant CRS should therefore be diagnosed in symptomatic patients after an 373 374 exhaustive differential diagnosis.

Two cases of severe COVID-19 (95% CI [1.6%,22.5%]) occurred in our unvaccinated cohort but none in our vaccinated patients. We observed induction of neutralizing antibodies after vaccination thus corroborating current evidence that COVID-19 vaccines may have meaningful activity in ICT-treated cancer patients (Fendler et al., 2021) (Strobel et al, manuscript in revision).

Vaccinated patients also showed increased overall survival (OS) in our study and vaccination status was an independent predictor of OS in a Cox proportional-hazards model. This observation cannot be explained by COVID-19 related mortality of unvaccinated patients alone. In unvaccinated patients only one in nine deaths was caused directly by COVID-19 and another one from tumor progression shortly after COVID-19 infection. Because patients

385 underwent regular rapid antigen-testing (q1w-q4w) it seems unlikely that we missed a relevant 386 number of COVID-19 cases. It is also possible that the small sample size of our heterogenous 387 cohort has skewed the survival analysis despite the similarity of vaccinated and unvaccinated 388 patients in many clinical covariates. Our results should therefore be validated in larger patient 389 cohorts. Alternatively, patients with worse disease status and symptoms may be more hesitant 390 and less likely to get vaccinated. This hypothesis is supported by the fact that unvaccinated 391 patients experienced numerically more severe adverse events even though this difference 392 was not statistically significant. This observation may also be a result of increased health 393 awareness or higher compliance regarding oncological therapy in vaccinated patients, an 394 outcome we did not assess in this study. Another possible explanation is that the cytokine boost induced by vaccination may have reinforced anti-tumor immunity. Specifically, IL-2 395 induction, as observed in our vaccinated patients, can break ICT resistance in subcutaneous 396 397 murine models (Sun et al., 2019). Overall, the tested COVID-19 vaccines were linked to favorable outcomes in our study and may have meaningful clinical activity in ICT treated 398 cancer patients. 399

400 Despite these important insights, our study also has several limitations which should be 401 considered in its interpretation. Adverse events under SARS-CoV-2 vaccination were not the 402 primary endpoint of this study. Therefore, sample size was not optimized for this endpoint and our trial is not powered to estimate the exact frequency of rare AE under ICT and COVID-19 403 vaccination. Moreover, AE were assessed upon presentation at our day clinic every 1-6 weeks 404 and not at a standardized early timepoint as performed for randomized controlled vaccination 405 trials (Polack et al., 2020). While serious AEs were generally reported instantly, lower grade 406 AEs may be underreported due to recall bias. Finally, all serum cytokine and antibody titer 407 analyses are research grade and absolute concentrations from this study should not be used 408 409 to establish clinical diagnoses. Strengths of our analysis include the prospective design, prospective recruitment of most patients, long-term follow-up, broad array of cancer types and 410 combination ICTs. 411

In summary, induction of CRS-related cytokines after COVID-19 vaccination is common in ICT-treated cancer patients, but generally clinically inapparent and hence not sufficient to define CRS. Our study supports current clinical practice of COVID-19 vaccination in cancer patients under ICT.

416

417 Methods

418 <u>Clinical trial</u>

Patients presented in this study are part of the exploration cohort of a prospectively registered 419 cohort study (DRKS00022890). The exploration cohort consisted of 220 patients of which 166 420 421 were recruited prospectively and 54 retrospectively. Adult patients with advanced solid tumors 422 starting a new cancer immunotherapy either as mono- or combination therapy except adoptive 423 cell therapies were eligible for inclusion. Informed consent, hemoglobin levels ≥8g/dl when 424 additional blood samples were obtained and measurable disease according to RECIST 1.1 were obligatory requirements for inclusion. Patients were followed up at least every 1-6 weeks 425 426 depending on the treatment regimen. Adverse events (AE) were retrieved from electronic patient health records and graded according to CTCAE v5.0 as per trial protocol. Other 427 metadata collected included age at time of informed consent, sex, tumor type, stage and 428 histology, mutational status, sites of metastases, history of tobacco use, pre-existing health 429 430 conditions, concurrent medication and survival. Pre-existing health conditions were obtained from electronic patient records and defined according to the Side Effect Resource (SIDER 431 432 v4.1, http://sideeffects.embl.de). Patients also received regular (q1-q4w) clinical laboratory tests including creatinine, bilirubin, CRP, hemoglobin, platelet, and leukocyte counts. 433 434 Additionally, patients received longitudinal blood samples for cytokine measurements before 435 the start of therapy, within 1-7 weeks after therapy initiation and every 8-12 weeks under immunotherapy. COVID-19 vaccination status was assessed during regular follow-up. 436 437 Patients did not undergo any additional screening for determination of vaccination status.

The primary outcome measure of the trial was prediction of radiological response which will be reported elsewhere. Secondary outcome measures included the serum proteome and peripheral blood immune cell composition overall, grade 3 adverse events as well as progression-free and overall survival. Patient health information is pseudonymized. The study size was defined by sample size estimation based on the primary outcome parameter.

The trial was conducted in accordance with the declaration of Helsinki in its current edition. The trial received institutional ethics review board approval at Ethics Commission I Medical Faculty Heidelberg, Heidelberg University (S-373/2020, S-207/2005,) and Ethics Commission II Medical Faculty Mannheim, Heidelberg University (2021-567). Trial personal was subject to medical confidentiality (§ 9 Abs. 1 MBO-Ä), the general data protection regulation (DSGVO) and the data protection act of the state of Baden-Württemberg (LSDG).

449 Analysis of serum cytokines and neutralizing antibodies

450 Blood was collected either peripherally or via a port catheter in coagulation matrix containing serum tubes (#01.1602, Sarstedt, Germany). Samples were kept at room temperature until 451 452 preparation (<24h). For serum preparation, tubes were centrifuged at 2500g for 10min at room 453 temperature, and the upper phase was transferred into 500µl aliquots and stored at -80°C. For both cytokine and antibody analysis we only selected patients with baseline samples not 454 455 older than 6 months prior to vaccination. For cytokine analysis we selected all samples obtained up to 4 weeks after the 2nd vaccination dose. For antibody analysis we selected all 456 457 samples until the end of follow-up.

Serum samples were thawed and immediately analyzed in duplicates using the Legendplex Cytokine Storm Panel 1 (741091, Biolegend, CA, USA), Cytokine Storm Panel 2 (741142, Biolegend, CA, USA) or SARS-CoV-2 Neutralizing Antibody Assay (741127, Biolegend, CA, USA) according to manufacturer's instructions and analyzed on a BD FACS Canto II flow cytometer (BD, NJ, USA). Analyte concentrations were interpolated from a standard curve using 5 parameter logistic regression using Legendplex Software v 2021.07.01. Cytokine

464 concentrations below the lower limit of detection were set to 0. The acquisition and processing
465 of the raw data was performed by a clinician scientist who was blinded to the patients' identity
466 and metadata and who was not involved in downstream data analysis. Notably, the patients'
467 pseudonyms contained the temporal sequence of the samples.

468 <u>General data analysis</u>

All data analysis was performed using Python 3 in a Jupyter notebook or Graph Pad Prism
9.2.0 (GraphPad Software Inc, CA, U.S.A.). All computer code is provided under
(https://github.com/wallet-maker/ANTICIPATE_COVID-19.git). Plotting was done using the
Matplotlib (3.4.3) and Seaborn (0.11.2) packages. Plots were arranged using Adobe Illustrator
2021 (25.2.2, Adobe Inc, San Jose, CA, USA).

474 Bootstrapping clustering probabilities of cytokine-cytokine pairs

We transformed cytokine concentrations according to the following formula $c_t = {}_{10}log(c+1)$ with 475 476 ct as the log-1p-transformed cytokine concentration and c as the raw cytokine concentration in pg/ml for all vaccinated patients. We then normalized all post vaccination log-1p transformed 477 478 concentrations by subtracting the respective log1p transformed cytokine concentrations of the baseline sample. Based on these normalized concentrations, we then calculated a spearman 479 cytokine-cytokine correlation matrix. We calculated pairwise Euclidian distances using scipy's 480 (1.7.2) scipy.spatial.distance.pdist function. Using scipy's scipy.cluster.hierarchy.linkage 481 482 function with the UPGMA method, we obtained the row and column linkages from the untransposed and transposed Euclidian distance matrix respectively and transformed these 483 484 into flat clusters by applying scipy.cluster.hierarchy.fcluster function using a cophenetic distance of 1.6. 485

We sampled the normalized log1p transformed cytokine concentration dataframe object with replacement with the same sample size as the initial dataframe and repeated the abovementioned procedure to obtain flat clusters. This sampling and clustering was repeated n=10,000 times. For each pair of cytokines we then counted their co-occurrence in a cluster

and summed the values for all 10,000 separate clusterings dividing the counts for each pair of
cytokines by 10 000 to obtain an approximation of the probability for each pair of cytokines to
fall into the same cluster.

493 Survival analysis

494 Survival was analyzed by Kaplan-Meier curves and Log-rank tests (Mantel-Cox) using GraphPad Prism and the lifelines package (0.26.3). We inspected the Kaplan-Meier curves 495 and did not see any obvious violation of the proportional hazards assumption. Using the 496 lifelines package, we also calculated a Cox-proportional hazards model using sex, age at trial 497 inclusion, stage, ECOG and vaccination status. We excluded BMI, tumor type and therapy 498 499 type. BMI was not available for several patients which would have decreased the population size. When including therapy type and tumor type the Cox model did not converge, likely due 500 to the large number of categories for these variables. When no events were observed in one 501 502 group we reported hazard-ratios using the Mantel-Hanszel method implemented in Graph Pad 503 Prism 9.2.0. Otherwise, we used the logrank method implemented in Graph Pad Prism 9.2.0.

504 Propensity score matching

Propensity score matching was performed using the pymatch package (0.3.4). Propensity scores were calculated for each patient based on age and sex. Based on these propensity scores we assigned each unvaccinated patient a vaccinated counterpart with replacement. This led to efficient matching, defined as a reduction in the age and sex imbalance of the vaccinated and unvaccinated cohorts (Figure S2B). We did not include other variables into the calculation of the propensity score because they led to inefficient matching with greater imbalance of the cohorts after matching.

After matching the patients, we calculated the interval from start of immunotherapy to the first COVID-19 vaccination for each vaccinated patient. By adding this interval to the start date of immunotherapy of the respective matched unvaccinated patient we created a 'virtual'

vaccination date for each unvaccinated patient. We then compared adverse events of
vaccinated and unvaccinated patients after this (virtual) vaccination date.

517 Statistical analysis and estimation of CRS frequency

518 Confidence intervals for CRS frequencies were calculated as Clopper-Pearson intervals 519 based on the beta distribution using the statsmodels.stats.proportion.proportion confint 520 function of the statsmodels package (0.10.2). P values were calculated using Wilcoxon one sample tests or Wilcoxon matched-pairs signed rank tests for continuous/ordinal one sample 521 or paired two sample data respectively using scipy's scipy.stats.wilcoxon function (1.7.2). For 522 categorical data/contingency tables we used Fisher's exact test (GraphPad Prism 9.2.0). All p 523 524 values are two-tailed. For cytokine data analysis p values were corrected for multiple comparisons with the Benjamini&Hochberg method using R 4.1.1 and the p.adjust function. 525 For clinical data analysis we did not use multiple comparisons correction to increase our power 526 527 to detect differences vaccine-related adverse events (which we did not find).

528 **Conflicts of interest:**

- 529 Thomas Walle reports previous and current stock ownership of various pharmaceutical
- 530 companies manufacturing SARS-CoV-2 vaccines and diagnostics including BionTech, Astra-
- 531 Zeneca and Roche. Thomas Walle reports research support from CanVirex, Basel,
- 532 Switzerland, a company developing viral vector-based immunotherapies and vaccines
- 533 (financial support for blood sampling materials). Guy Ungerechts is founder and current
- 534 CMO/CSO of CanVirex. All other authors report no conflicts of interest.

535 Author contributions:

- 536 Conceptualization: T.W.
- 537 Methodology: T.W. J.A.K., R.K.
- 538 Computer Code: T.W.
- 539 Investigation: T.W., S.B., J.A.K., B.H., L.Z., R.S., M.W., S.P.,

- 540 Patient recruitment: T.W., K.K., C.C., S.S, T.R, L.J.M., J.B., M.J., C.F., S.K., A.S., K.S., S.K.,
- 541 C.S-T., C.S., J.B., T.D., E.B., M.C., X.Z., A.R., M.S., F.M., M.L., A.S., D.J., J.K., G.M.H., S.Z.,
- 542 A.B., N.H., R.K., J.H.
- 543 Writing Original Draft: T.W.,
- 544 Writing Review and Editing: T.W., S.B., G.U., J.A.K., G.M.H, A.B., C.S.
- 545 Visualization: T.W., S.B.
- 546 Funding Acquisition: T.W., G.U.
- 547 Supervision: G.U.
- 548 Statistical consultation: J.K., R.K.
- 549 Funding
- 550 DKFZ Clinician Scientist Program, supported by the Dieter Morszeck Foundation to T.W
- 551 National Center for Tumor Diseases (NCT) Heidelberg, Heidelberg, Germany
- 552 German Cancer Research Center (DKFZ), Heidelberg, Germany
- 553 CanVirex, Basel, Switzerland to T.W./G.U.

554 Acknowledgements

- 555 We thank all participating patients and their relatives for their consent to this research. We
- thank the NCT Day Clinic 1, Day Clinic 2 and Dermatology Outpatient Clinic nursing staff for
- 557 blood sampling. We thank DKFZ Flow Cytometry Core Facility for technical support and
- 558 infrastructure. T.W. and A.S. have been funded by a fellowship of the DKFZ Clinician
- 559 Scientist Program, supported by the Dieter Morszeck Foundation.
- 560 Data availability statement
- 561 All relevant data and code is supplied with the manuscript (https://github.com/wallet-
- 562 <u>maker/ANTICIPATE COVID-19.git</u>). Patient material of patients who have given consent for
- 563 further analyses can be requested after approval of Ethics Commission I, Medical Faculty
- 564 Heidelberg, Heidelberg University. No custom materials have been generated during this
- 565 study.

566 **References**

perpetuity. It is made available under a CC-BY 4.0 International license .

- 567 Au, L., Fendler, A., Shepherd, S. T. C., Rzeniewicz, K., Cerrone, M., Byrne, F., Carlyle, E., Edmonds, K., 568 Del Rosario, L., Shon, J., Haynes, W. A., Ward, B., Shum, B., Gordon, W., Gerard, C. L., Xie, W., 569 Joharatnam-Hogan, N., Young, K., Pickering, L., Furness, A. J. S., Larkin, J., Harvey, R., Kassiotis, G., Gandhi, S., Kassiotis, G., Gandhi, S., Swanton, C., Swanton, C., Fribbens, C., Wilkinson, K. 570 571 A., Wilkinson, R. J., Lau, D. K., Banerjee, S., Starling, N., Chau, I., Au, L., Fendler, A., Shepherd, 572 S. T. C., Byrne, F., Shum, B., Gerard, C., Young, K., Pickering, L., Furness, A. J. S., Larkin, J., 573 Kassiotis, G., Wilkinson, K. A., Wilkinson, R. J., Baneriee, S., Starling, N., Chau, I., Turajlic, S., 574 Turajlic, S., Crick, C.-C., & Consortium, C. (2021). Cytokine release syndrome in a patient with 575 colorectal cancer after vaccination with BNT162b2. Nature Medicine. 576 https://doi.org/10.1038/s41591-021-01387-6
- Baden, L. R., El Sahly, H. M., Essink, B., Kotloff, K., Frey, S., Novak, R., Diemert, D., Spector, S. A.,
 Rouphael, N., Creech, C. B., McGettigan, J., Khetan, S., Segall, N., Solis, J., Brosz, A., Fierro, C.,
 Schwartz, H., Neuzil, K., Corey, L., Gilbert, P., Janes, H., Follmann, D., Marovich, M., Mascola,
 J., Polakowski, L., Ledgerwood, J., Graham, B. S., Bennett, H., Pajon, R., Knightly, C., Leav, B.,
 Deng, W., Zhou, H., Han, S., Ivarsson, M., Miller, J., & Zaks, T. (2020). Efficacy and Safety of the
 mRNA-1273 SARS-CoV-2 Vaccine. *New England Journal of Medicine*, *384*(5), 403-416.
 https://doi.org/10.1056/NEJMoa2035389
- Chen, L. Y. C., Hoiland, R. L., Stukas, S., Wellington, C. L., & Sekhon, M. S. (2021). Assessing the
 importance of interleukin-6 in COVID-19. *The Lancet Respiratory Medicine*, 9(2), e13.
 https://doi.org/10.1016/S2213-2600(20)30600-7
- Fajgenbaum, D. C., & June, C. H. (2020). Cytokine Storm. *New England Journal of Medicine*, 383(23),
 2255-2273. <u>https://doi.org/10.1056/NEJMra2026131</u>
- 589 Fendler, A., Shepherd, S. T. C., Au, L., Wilkinson, K. A., Wu, M., Byrne, F., Cerrone, M., Schmitt, A. M., Joharatnam-Hogan, N., Shum, B., Tippu, Z., Rzeniewicz, K., Boos, L. A., Harvey, R., Carlyle, E., 590 591 Edmonds, K., Del Rosario, L., Sarker, S., Lingard, K., Mangwende, M., Holt, L., Ahmod, H., 592 Korteweg, J., Foley, T., Bazin, J., Gordon, W., Barber, T., Emslie-Henry, A., Xie, W., Gerard, C. 593 L., Deng, D., Wall, E. C., Agua-Doce, A., Namjou, S., Caidan, S., Gavrielides, M., MacRae, J. I., 594 Kelly, G., Peat, K., Kelly, D., Murra, A., Kelly, K., O'Flaherty, M., Dowdie, L., Ash, N., Gronthoud, 595 F., Shea, R. L., Gardner, G., Murray, D., Kinnaird, F., Cui, W., Pascual, J., Rodney, S., Mencel, J., 596 Curtis, O., Stephenson, C., Robinson, A., Oza, B., Farag, S., Leslie, I., Rogiers, A., Iyengar, S., 597 Ethell, M., Messiou, C., Cunningham, D., Chau, I., Starling, N., Turner, N., Welsh, L., van As, N., 598 Jones, R. L., Droney, J., Banerjee, S., Tatham, K. C., O'Brien, M., Harrington, K., Bhide, S., 599 Okines, A., Reid, A., Young, K., Furness, A. J. S., Pickering, L., Swanton, C., Gandhi, S., Gamblin, 600 S., Bauer, D. L. V., Kassiotis, G., Kumar, S., Yousaf, N., Jhanji, S., Nicholson, E., Howell, M., 601 Walker, S., Wilkinson, R. J., Larkin, J., Turajlic, S., The Crick, C.-C., & The, C. C. (2021). Adaptive 602 immunity and neutralizing antibodies against SARS-CoV-2 variants of concern following 603 vaccination in patients with cancer: the CAPTURE study. Nature Cancer. 604 https://doi.org/10.1038/s43018-021-00274-w
- Folegatti, P. M., Ewer, K. J., Aley, P. K., Angus, B., Becker, S., Belij-Rammerstorfer, S., Bellamy, D., Bibi, 605 606 S., Bittaye, M., Clutterbuck, E. A., Dold, C., Faust, S. N., Finn, A., Flaxman, A. L., Hallis, B., Heath, 607 P., Jenkin, D., Lazarus, R., Makinson, R., Minassian, A. M., Pollock, K. M., Ramasamy, M., 608 Robinson, H., Snape, M., Tarrant, R., Voysey, M., Green, C., Douglas, A. D., Hill, A. V. S., Lambe, 609 T., Gilbert, S. C., Pollard, A. J., Aboagye, J., Adams, K., Ali, A., Allen, E., Allison, J. L., Anslow, R., 610 Arbe-Barnes, E. H., Babbage, G., Baillie, K., Baker, M., Baker, N., Baker, P., Baleanu, I., 611 Ballaminut, J., Barnes, E., Barrett, J., Bates, L., Batten, A., Beadon, K., Beckley, R., Berrie, E., Berry, L., Beveridge, A., Bewley, K. R., Bijker, E. M., Bingham, T., Blackwell, L., Blundell, C. L., 612 613 Bolam, E., Boland, E., Borthwick, N., Bower, T., Boyd, A., Brenner, T., Bright, P. D., Brown-614 O'Sullivan, C., Brunt, E., Burbage, J., Burge, S., Buttigieg, K. R., Byard, N., Cabera Puig, I., Calvert, A., Camara, S., Cao, M., Cappuccini, F., Carr, M., Carroll, M. W., Carter, V., Cathie, K., 615 616 Challis, R. J., Charlton, S., Chelysheva, I., Cho, J.-S., Cicconi, P., Cifuentes, L., Clark, H., Clark, E., 617 Cole, T., Colin-Jones, R., Conlon, C. P., Cook, A., Coombes, N. S., Cooper, R., Cosgrove, C. A.,

perpetuity. It is made available under a CC-BY 4.0 International license .

618 Coy, K., Crocker, W. E. M., Cunningham, C. J., Damratoski, B. E., Dando, L., Datoo, M. S., Davies, 619 H., De Graaf, H., Demissie, T., Di Maso, C., Dietrich, I., Dong, T., Donnellan, F. R., Douglas, N., 620 Downing, C., Drake, J., Drake-Brockman, R., Drury, R. E., Dunachie, S. J., Edwards, N. J., 621 Edwards, F. D. L., Edwards, C. J., Elias, S. C., Elmore, M. J., Emary, K. R. W., English, M. R., 622 Fagerbrink, S., Felle, S., Feng, S., Field, S., Fixmer, C., Fletcher, C., Ford, K. J., Fowler, J., Fox, P., 623 Francis, E., Frater, J., Furze, J., Fuskova, M., Galiza, E., Gbesemete, D., Gilbride, C., Godwin, K., 624 Gorini, G., Goulston, L., Grabau, C., Gracie, L., Gray, Z., Guthrie, L. B., Hackett, M., Halwe, S., 625 Hamilton, E., Hamlyn, J., Hanumunthadu, B., Harding, I., Harris, S. A., Harris, A., Harrison, D., 626 Harrison, C., Hart, T. C., Haskell, L., Hawkins, S., Head, I., Henry, J. A., Hill, J., Hodgson, S. H. C., 627 Hou, M. M., Howe, E., Howell, N., Hutlin, C., Ikram, S., Isitt, C., Iveson, P., Jackson, S., Jackson, 628 F., James, S. W., Jenkins, M., Jones, E., Jones, K., Jones, C. E., Jones, B., Kailath, R., Karampatsas, 629 K., Keen, J., Kelly, S., Kelly, D., Kerr, D., Kerridge, S., Khan, L., Khan, U., Killen, A., Kinch, J., King, 630 T. B., King, L., King, J., Kingham-Page, L., Klenerman, P., Knapper, F., Knight, J. C., Knott, D., 631 Koleva, S., Kupke, A., Larkworthy, C. W., Larwood, J. P. J., Laskey, A., Lawrie, A. M., Lee, A., 632 Ngan Lee, K. Y., Lees, E. A., Legge, H., Lelliott, A., Lemm, N.-M., Lias, A. M., Linder, A., Lipworth, 633 S., Liu, X., Liu, S., Lopez Ramon, R., Lwin, M., Mabesa, F., Madhavan, M., Mallett, G., Mansatta, 634 K., Marcal, I., Marinou, S., Marlow, E., Marshall, J. L., Martin, J., McEwan, J., McInroy, L., Meddaugh, G., Mentzer, A. J., Mirtorabi, N., Moore, M., Moran, E., Morey, E., Morgan, V., 635 636 Morris, S. J., Morrison, H., Morshead, G., Morter, R., Mujadidi, Y. F., Muller, J., Munera-637 Huertas, T., Munro, C., Munro, A., Murphy, S., Munster, V. J., Mweu, P., Noé, A., Nugent, F. L., 638 Nuthall, E., O'Brien, K., O'Connor, D., Oguti, B., Oliver, J. L., Oliveira, C., O'Reilly, P. J., Osborn, 639 M., Osborne, P., Owen, C., Owens, D., Owino, N., Pacurar, M., Parker, K., Parracho, H., Patrick-640 Smith, M., Payne, V., Pearce, J., Peng, Y., Peralta Alvarez, M. P., Perring, J., Pfafferott, K., Pipini, 641 D., Plested, E., Pluess-Hall, H., Pollock, K., Poulton, I., Presland, L., Provstgaard-Morys, S., 642 Pulido, D., Radia, K., Ramos Lopez, F., Rand, J., Ratcliffe, H., Rawlinson, T., Rhead, S., Riddell, 643 A., Ritchie, A. J., Roberts, H., Robson, J., Roche, S., Rohde, C., Rollier, C. S., Romani, R., 644 Rudiansyah, I., Saich, S., Sajjad, S., Salvador, S., Sanchez Riera, L., Sanders, H., Sanders, K., 645 Sapaun, S., Sayce, C., Schofield, E., Screaton, G., Selby, B., Semple, C., Sharpe, H. R., Shaik, I., 646 Shea, A., Shelton, H., Silk, S., Silva-Reyes, L., Skelly, D. T., Smee, H., Smith, C. C., Smith, D. J., 647 Song, R., Spencer, A. J., Stafford, E., Steele, A., Stefanova, E., Stockdale, L., Szigeti, A., Tahiri-Alaoui, A., Tait, M., Talbot, H., Tanner, R., Taylor, I. J., Taylor, V., Te Water Naude, R., Thakur, 648 649 N., Themistocleous, Y., Themistocleous, A., Thomas, M., Thomas, T. M., Thompson, A., Thomson-Hill, S., Tomlins, J., Tonks, S., Towner, J., Tran, N., Tree, J. A., Truby, A., Turkentine, 650 651 K., Turner, C., Turner, N., Turner, S., Tuthill, T., Ulaszewska, M., Varughese, R., Van Doremalen, 652 N., Veighey, K., Verheul, M. K., Vichos, I., Vitale, E., Walker, L., Watson, M. E. E., Welham, B., 653 Wheat, J., White, C., White, R., Worth, A. T., Wright, D., Wright, S., Yao, X. L., & Yau, Y. (2020). 654 Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. The Lancet, 655 656 396(10249), 467-478. https://doi.org/10.1016/S0140-6736(20)31604-4

- Frenck, R. W., Klein, N. P., Kitchin, N., Gurtman, A., Absalon, J., Lockhart, S., Perez, J. L., Walter, E. B.,
 Senders, S., Bailey, R., Swanson, K. A., Ma, H., Xu, X., Koury, K., Kalina, W. V., Cooper, D.,
 Jennings, T., Brandon, D. M., Thomas, S. J., Türeci, Ö., Tresnan, D. B., Mather, S., Dormitzer, P.
 R., Şahin, U., Jansen, K. U., & Gruber, W. C. (2021). Safety, Immunogenicity, and Efficacy of the
 BNT162b2 COVID-19 Vaccine in Adolescents. *New England Journal of Medicine*.
 https://doi.org/10.1056/NEJMoa2107456
- Galván-Román, J. M., Rodríguez-García, S. C., Roy-Vallejo, E., Marcos-Jiménez, A., Sánchez-Alonso, S.,
 Fernández-Díaz, C., Alcaraz-Serna, A., Mateu-Albero, T., Rodríguez-Cortes, P., SánchezCerrillo, I., Esparcia, L., Martínez-Fleta, P., López-Sanz, C., Gabrie, L., del Campo Guerola, L.,
 Suárez-Fernández, C., Ancochea, J., Canabal, A., Albert, P., Rodríguez-Serrano, D. A., Aguilar,
 J. M., del Arco, C., de los Santos, I., García-Fraile, L., de la Cámara, R., Serra, J. M., Ramírez, E.,
 Alonso, T., Landete, P., Soriano, J. B., Martín-Gayo, E., Fraile Torres, A., Zurita Cruz, N. D.,

perpetuity. It is made available under a CC-BY 4.0 International license .

669 García-Vicuña, R., Cardeñoso, L., Sánchez-Madrid, F., Alfranca, A., Muñoz-Calleja, C., González-670 Álvaro, I., Alvarado, T., Martínez, P., Javier de la Cuerda Llorente, F., Arco, C. d., Aguilar, J. M., Villalba, N., Negro, M., Contreras, E., Rey, A. d., Santiago, C., Junquera, M., Caminero, R., Val, 671 672 F. J., González, S., Caño, M., López, I., von Wernitz, A., Retana, B., Guerra, I., Sorando, J., Chao, 673 L., Cárdenas, M. J., Espiga, V., Chicharro, P., Rodríguez, P., Alday, I. H., Sampedro, M., Prada, 674 J., Aldama, E. R., Real, Y., Caldas, M., Casabona, S., Lanas-Gimeno, A., Camara, R. d. l., Alvárez, A. F., Aguadol, B., Morell, A., Ramírez, E., Zurriaga, A. I., Abanades, M. P., García, S. R., Aranda, 675 676 T. G., Ruiz, M., Nieto, C. M., Serra, J. M., Sánchez-Madrid, F., Muñoz-Calleja, C., Alfranca, A., 677 Aspa, J., Marcos-Jiménez, A., Sánchez-Alonso, S., Alcaraz-Serna, A., Mateu-Albero, T., Sánchez-678 Cerrillo, I., Esparcia, L., Martínez-Fleta, P., López-Sanz, C., Gabrie, L., Guerola, L. d. C., 679 Fernández, E., Calzada, M. J., Tejedor, R., Canabal, A., Albert, P., Rodríguez-Serrano, D. A., 680 Iglesias, J., Suarez, F., Sánchez, J. A., Abad, B., Suarez, C., Santos, I. d. l., Galván-Román, J. M., 681 Roy, E., Rodríguez-Cortes, P., García-Fraile, L., Sanz, J., Sanchez, E., Moldenhauer, F., Casado, 682 P., Curbelo, J., Gutierrez, A., Bautista, A., Giménez, N. R., Fernandez, A., Parra, P., Moyano, B., 683 Barrios, A., Real de Asua, D., Sanchez, B., Saez, C., Ciudad, M., Navas, D., Domingo, L. C., 684 Torresano, M. d. C. C., García, D. D., Cavero, T. A., Blanco, A. G., Ramírez, A. M., Semiglia 685 Chong, M. A., Cobos, A. G., Zurita Cruz, N. D., Fraile Torres, A. M., Sanchez-Gonzalez, C., 686 Perpén, A. F., Pérez, C. D., Ancochea, J., Alonso, T., Landete, P., Soriano, J., Cisneros, C., 687 Castillo, E. G., García Pérez, F. J., Girón, R. M., Marcos, C., Zamora, E., García, P. G., Castañeda, 688 S., García-Vicuña, R., González-Álvaro, I., Rodríguez-García, S., Fernández-Díaz, C., Cubas, I. L., 689 Tomero, E. G., Castañeda, N. G., Ortiz, A. M., Valero, C., Uriarte, M., & Montes, N. (2021). IL-6 690 serum levels predict severity and response to tocilizumab in COVID-19: An observational 691 study. Journal of Allergy and Clinical Immunology, 147(1), 72-80.e78. 692 https://doi.org/10.1016/j.jaci.2020.09.018

- Haslam, A., & Prasad, V. (2019). Estimation of the Percentage of US Patients With Cancer Who Are
 Eligible for and Respond to Checkpoint Inhibitor Immunotherapy Drugs. JAMA Network Open,
 2(5), e192535-e192535. https://doi.org/10.1001/jamanetworkopen.2019.2535
- Hay, K. A., Hanafi, L.-A., Li, D., Gust, J., Liles, W. C., Wurfel, M. M., López, J. A., Chen, J., Chung, D.,
 Harju-Baker, S., Cherian, S., Chen, X., Riddell, S. R., Maloney, D. G., & Turtle, C. J. (2017).
 Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen
 receptor–modified T-cell therapy. *Blood*, *130*(21), 2295-2306. <u>https://doi.org/10.1182/blood-</u>
 2017-06-793141
- Iorgulescu, J. B., Gokhale, P. C., Speranza, M. C., Eschle, B. K., Poitras, M. J., Wilkens, M. K., Soroko, K.
 M., Chhoeu, C., Knott, A., Gao, Y., Lim-Fat, M. J., Baker, G. J., Bonal, D. M., Nguyen, Q.-D.,
 Grant, G. R. L., Ligon, K. L., Sorger, P. K., Chiocca, E. A., Anderson, A. C., Kirschmeier, P. T.,
 Sharpe, A. H., Freeman, G. J., & Reardon, D. A. (2021). Concurrent Dexamethasone Limits the
 Clinical Benefit of Immune Checkpoint Blockade in Glioblastoma. *Clinical Cancer Research*,
 27(1), 276-287. https://doi.org/10.1158/1078-0432.Ccr-20-2291
- Lee, D. W., Santomasso, B. D., Locke, F. L., Ghobadi, A., Turtle, C. J., Brudno, J. N., Maus, M. V., Park, J.
 H., Mead, E., Pavletic, S., Go, W. Y., Eldjerou, L., Gardner, R. A., Frey, N., Curran, K. J., Peggs,
 K., Pasquini, M., DiPersio, J. F., van den Brink, M. R. M., Komanduri, K. V., Grupp, S. A., &
 Neelapu, S. S. (2019). ASTCT Consensus Grading for Cytokine Release Syndrome and
 Neurologic Toxicity Associated with Immune Effector Cells. *Biology of Blood and Marrow Transplantation*, *25*(4), 625-638. <u>https://doi.org/10.1016/j.bbmt.2018.12.758</u>
- Liang, F., Lindgren, G., Lin, A., Thompson, E. A., Ols, S., Röhss, J., John, S., Hassett, K., Yuzhakov, O., 713 714 Bahl, K., Brito, L. A., Salter, H., Ciaramella, G., & Loré, K. (2017). Efficient Targeting and 715 Activation of Antigen-Presenting Cells In Vivo after Modified mRNA Vaccine 716 Administration Rhesus Macaques. Molecular Therapy, in 25(12), 2635-2647. https://doi.org/10.1016/j.ymthe.2017.08.006 717
- Maslov, D. V., Tawagi, K., KC, M., Simenson, V., Yuan, H., Parent, C., Bamnolker, A., Goel, R., Blake, Z.,
 Matrana, M. R., & Johnson, D. H. (2021). Timing of steroid initiation and response rates to

perpetuity. It is made available under a CC-BY 4.0 International license .

720 immune checkpoint inhibitors in metastatic cancer. Journal for ImmunoTherapy of Cancer, 721 9(7), e002261. https://doi.org/10.1136/jitc-2020-002261

- 722 Monin, L., Laing, A. G., Muñoz-Ruiz, M., McKenzie, D. R., del Molino del Barrio, I., Alaguthurai, T., 723 Domingo-Vila, C., Hayday, T. S., Graham, C., Seow, J., Abdul-Jawad, S., Kamdar, S., Harvey-724 Jones, E., Graham, R., Cooper, J., Khan, M., Vidler, J., Kakkassery, H., Sinha, S., Davis, R., 725 Dupont, L., Francos Quijorna, I., O'Brien-Gore, C., Lee, P. L., Eum, J., Conde Poole, M., Joseph, 726 M., Davies, D., Wu, Y., Swampillai, A., North, B. V., Montes, A., Harries, M., Rigg, A., Spicer, J., 727 Malim, M. H., Fields, P., Patten, P., Di Rosa, F., Papa, S., Tree, T., Doores, K. J., Hayday, A. C., & 728 Irshad, S. (2021). Safety and immunogenicity of one versus two doses of the COVID-19 vaccine 729 BNT162b2 for patients with cancer: interim analysis of a prospective observational study. The 730 Lancet Oncology, 22(6), 765-778. https://doi.org/10.1016/S1470-2045(21)00213-8
- Pelka, K., Hofree, M., Chen, J. H., Sarkizova, S., Pirl, J. D., Jorgji, V., Bejnood, A., Dionne, D., Ge, W. H., 731 732 Xu, K. H., Chao, S. X., Zollinger, D. R., Lieb, D. J., Reeves, J. W., Fuhrman, C. A., Hoang, M. L., 733 Delorey, T., Nguyen, L. T., Waldman, J., Klapholz, M., Wakiro, I., Cohen, O., Albers, J., Smillie, 734 C. S., Cuoco, M. S., Wu, J., Su, M.-j., Yeung, J., Vijaykumar, B., Magnuson, A. M., Asinovski, N., 735 Moll, T., Goder-Reiser, M. N., Applebaum, A. S., Brais, L. K., DelloStritto, L. K., Denning, S. L., 736 Phillips, S. T., Hill, E. K., Meehan, J. K., Frederick, D. T., Sharova, T., Kanodia, A., Todres, E. Z., 737 Jané-Valbuena, J., Biton, M., Izar, B., Lambden, C. D., Clancy, T. E., Bleday, R., Melnitchouk, N., 738 Irani, J., Kunitake, H., Berger, D. L., Srivastava, A., Hornick, J. L., Ogino, S., Rotem, A., Vigneau, 739 S., Johnson, B. E., Corcoran, R. B., Sharpe, A. H., Kuchroo, V. K., Ng, K., Giannakis, M., Nieman, L. T., Boland, G. M., Aguirre, A. J., Anderson, A. C., Rozenblatt-Rosen, O., Regev, A., & Hacohen, 740 741 N. Spatially organized multicellular immune hubs in human colorectal cancer. Cell. 742 https://doi.org/10.1016/j.cell.2021.08.003
- 743 Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, 744 G., Moreira, E. D., Zerbini, C., Bailey, R., Swanson, K. A., Roychoudhury, S., Koury, K., Li, P., 745 Kalina, W. V., Cooper, D., Frenck, R. W., Hammitt, L. L., Türeci, Ö., Nell, H., Schaefer, A., Ünal, 746 S., Tresnan, D. B., Mather, S., Dormitzer, P. R., Şahin, U., Jansen, K. U., & Gruber, W. C. (2020). 747 Safety and Efficacy of the BNT162b2 mRNA COVID-19 Vaccine. New England Journal of 748 Medicine, 383(27), 2603-2615. https://doi.org/10.1056/NEJMoa2034577
- 749 Ribas, A., Sengupta, R., Locke, T., Zaidi, S. K., Campbell, K. M., Carethers, J. M., Jaffee, E. M., Wherry, 750 E. J., Soria, J.-C., & D'Souza, G. (2021). Priority COVID-19 Vaccination for Patients with Cancer 751 while Vaccine Supply ls Limited. Cancer Discovery, 233-236. 11(2), https://doi.org/10.1158/2159-8290.Cd-20-1817 752
- 753 Russell, B., Moss, C. L., Shah, V., Ko, T. K., Palmer, K., Sylva, R., George, G., Monroy-Iglesias, M. J., 754 Patten, P., Ceesay, M. M., Benjamin, R., Potter, V., Pagliuca, A., Papa, S., Irshad, S., Ross, P., 755 Spicer, J., Kordasti, S., Crawley, D., Wylie, H., Cahill, F., Haire, A., Zaki, K., Sita-Lumsden, A., 756 Josephs, D., Enting, D., Swampillai, A., Sawyer, E., D'Souza, A., Gomberg, S., Harrison, C., Fields, 757 P., Wrench, D., Rigg, A., Sullivan, R., Kulasekararaj, A., Jones, E., Seeva, P., Karampera, C., Devi, 758 A., Rahman, F., Smith, D., Owczarczyk, K., Tsotra, E., Gousis, C., Lei, M., Ghosh, S., Nintos, G., 759 Raj, K., Gleeson, M., Bailey, K., Dillon, R., Streetly, M., Mera, A., Timbres, J., Dolly, S., Van 760 Hemelrijck, M., & Guy's Cancer Real World, E. (2021). Risk of COVID-19 death in cancer 761 patients: an analysis from Guy's Cancer Centre and King's College Hospital in London. British Journal of Cancer, 125(7), 939-947. https://doi.org/10.1038/s41416-021-01500-z 762
- Sahin, U., Karikó, K., & Türeci, Ö. (2014). mRNA-based therapeutics developing a new class of drugs. 763 764 Nature Reviews Drug Discovery, 13(10), 759-780. https://doi.org/10.1038/nrd4278
- 765 Sahin, U., Muik, A., Derhovanessian, E., Vogler, I., Kranz, L. M., Vormehr, M., Baum, A., Pascal, K., Quandt, J., Maurus, D., Brachtendorf, S., Lörks, V., Sikorski, J., Hilker, R., Becker, D., Eller, A.-766 767 K., Grützner, J., Boesler, C., Rosenbaum, C., Kühnle, M.-C., Luxemburger, U., Kemmer-Brück, 768 A., Langer, D., Bexon, M., Bolte, S., Karikó, K., Palanche, T., Fischer, B., Schultz, A., Shi, P.-Y., 769 Fontes-Garfias, C., Perez, J. L., Swanson, K. A., Loschko, J., Scully, I. L., Cutler, M., Kalina, W., 770 Kyratsous, C. A., Cooper, D., Dormitzer, P. R., Jansen, K. U., & Türeci, Ö. (2020). COVID-19

- 771 vaccine BNT162b1 elicits human antibody and TH1 T cell responses. Nature, 586(7830), 594-599. https://doi.org/10.1038/s41586-020-2814-7 772
- 773 Sahin, U., Oehm, P., Derhovanessian, E., Jabulowsky, R. A., Vormehr, M., Gold, M., Maurus, D., 774 Schwarck-Kokarakis, D., Kuhn, A. N., Omokoko, T., Kranz, L. M., Diken, M., Kreiter, S., Haas, H., 775 Attig, S., Rae, R., Cuk, K., Kemmer-Brück, A., Breitkreuz, A., Tolliver, C., Caspar, J., Quinkhardt, 776 J., Hebich, L., Stein, M., Hohberger, A., Vogler, I., Liebig, I., Renken, S., Sikorski, J., Leierer, M., 777 Müller, V., Mitzel-Rink, H., Miederer, M., Huber, C., Grabbe, S., Utikal, J., Pinter, A., Kaufmann, 778 R., Hassel, J. C., Loquai, C., & Türeci, Ö. (2020). An RNA vaccine drives immunity in checkpoint-779 inhibitor-treated melanoma. Nature, 585(7823), 107-112. https://doi.org/10.1038/s41586-780 020-2537-9
- 781 Sun, Z., Ren, Z., Yang, K., Liu, Z., Cao, S., Deng, S., Xu, L., Liang, Y., Guo, J., Bian, Y., Xu, H., Shi, J., Wang, 782 F., Fu, Y.-X., & Peng, H. (2019). A next-generation tumor-targeting IL-2 preferentially promotes 783 tumor-infiltrating CD8+ T-cell response and effective tumor control. Nature Communications, 784 10. https://doi.org/10.1038/s41467-019-11782-w
- 785 Trapani, D., & Curigliano, G. (2021). COVID-19 vaccines in patients with cancer. The Lancet Oncology, 786 22(6), 738-739. https://doi.org/10.1016/S1470-2045(21)00250-3
- Waissengrin, B., Agbarya, A., Safadi, E., Padova, H., & Wolf, I. (2021). Short-term safety of the 787 788 BNT162b2 mRNA COVID-19 vaccine in patients with cancer treated with immune checkpoint 789 inhibitors. The Lancet Oncology, 22(5), 581-583. https://doi.org/10.1016/S1470-790 2045(21)00155-8